Optum Rx Picks Hyrimoz and Cyltezo for Its Formulary
The Sandoz's and Boehinger Ingelheim's Humira biosimilars will join Amgen's Amjevita on the formulary of UnitedHealth Group's PBM. Cyltezo may have a marketing edge because of its interchangeability designation.
One of the lingering doubts about biosimilars has been whether pharmacy benefit managers (PBM), especially the big three — Optum Rx, CVS Caremark and Express Scripts — would include them on their formularies, leading to coverage and prescriptions, or would the PBMs stick with the brand-name reference products because of rebates and other discounts that can reward the companies financially for sticking with drugs that have higher list prices.
Some doubt remains, partly because the PBM industry that is inscrutable in many ways. But today’s news that Optum Rx is going to add two more Humira (adalimumab) biosimilars may be a sign that formulary placement is receding as an obstacle to biosimilar prescribing and use.
Optum Rx announced this morning that it is going to include Sandoz’s Hyrimoz (adalimumab-adaz) and Boehinger Ingelheim’s Cyltezo (adalimumab-adbm) to its formulary at parity with Humira. Optum Rx, the PBM arm of the health services giant UnitedHealth Group, had previously put Amgen’s Amjevita (adalimumab-atto) on its formulary after it came on the market early this year.
Related: Tis the year of the Humira Biosimilars
"Optum Rx's decision to add Cyltezo to its formulary could benefit millions of Americans, improving access to a crucial medicine that has been a safe and effective treatment for many inflammatory conditions for the last two decades," said Stephen Pagnotta, executive director and biosimilar commercial lead at Boehringer Ingelheim, in a press release today.
“As an industry leader driving competition and biosimilar access, we are bringing unprecedented choice and value in this highly utilized but historically very expensive drug class,” said Heather Cianfrocco, Optum Rx’s CEO, said in a press release.
Optum Rx’s decision to cover three biosimilars was expected. Cianfrocco announced in late 2022 that the PBM would cover Amjevita and two others. The fresh news today was that Cyltezo and Hyrimoz got the nod.
Cyltezo may have a marked marketing advantage over the other Humira biosimilars because it is the only one so far with the interchangeable designation from the FDA. The designation means patients in trials have switched back and forth between Humira and the biosimilar without safety or and efficacy problems occurring. Surveys of doctors have found that they are more comfortable prescribing a biosimilar with the interchangeable designation.
Humira, once the world's top selling drug, still generated approximately $20 billion in revenue for AbbVie in 2022. It has powerful anti-inflammatory effects and is used to treat rheumatoid arthritis, Crohn’s disease, ulcerative colitis and other autoimmune diseases that are caused by a dysregulated immune system that has inflammatory aspects.
Through patent litigation and other means, AbbVie managed to keep Humira biosimilars off the market for years, but this year by virtue of a series of legal settlements between AbbVie and the biosimilar makers, the floodgates opened. Amgen got a jump on the competition with Amjevita. In July, five more Humira biosimilars are expected to come on the market in addition to Cyltezo and Hyrimoz.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More
